| 英文摘要 |
The transmission vectors of the dengue virus are primarily Aedes aegypti or Aedes albopictus mosquitoes. Most patients with dengue are asymptomatic or exhibit mild symptoms, which typically improve within 1 to 2 weeks. Symptoms usually appear 4–10 days after infection and last for 2–7 days. These symptoms include high fever, severe headache, retro-orbital pain, muscle and joint pain, nausea, vomiting, swollen lymph nodes, and rashes. Individuals who experienced a second infection are at an increased risk of developing severe dengue and often require hospitalization. In rare cases, dengue can progress to a severe form that may be fatal. Clinically, rapid diagnostic testing using the dengue nonstructural protein 1 (NS1) antigen test can quickly identify the disease. Although there is no specific or effective treatment for dengue, supportive care is crucial. Acetaminophen is commonly used to manage pain; however, non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and aspirin, should be avoided due to the risk of bleeding. Dengvaxia®(CYD-TDV) and Qdenga®(TAK-003) are two vaccines that can reduce the risk of contracting dengue; nevertheless, they are not yet available in Taiwan. Preventing mosquito bites, eliminating mosquito breeding sites, early case detection, recognizing warning signs of severe dengue, and appropriate case management are key strategies for preventing dengue infections and reducing mortality in severe cases. Dengue fever is a common mosquito-borne viral infectious disease that imposes a significant economic and public health burden on endemic regions. Therefore, dengue vaccines play a crucial role in disease control. This article reviews recent literature on the epidemiology, diagnosis, treatment, care, and prevention of dengue, aiming to provide healthcare professionals with the latest knowledge and references for patient care. |